Who We Are: PMK Group and Our Mission in Biotech | Clinical Capital Conversations
Biotech often fails for the wrong reasons. Nearly 60% of clinical trial failures are due to technical execution, not the science itself.
In this episode, Dr. Peter M. Kovacs explains why he founded PMK Group, a firm that combines capital with clinical and regulatory expertise to reduce technical failures and accelerate drug development.
Why it matters:
– Billions are lost to preventable execution failures
– Patients wait years for therapies that could be delivered faster
– Investors face unnecessary downside risk
PMK Group’s model is different: we do not just invest money. We invest experience, systems, and execution.
Subscribe to Clinical Capital Conversations for more insights at the crossroads of science and capital.
Timecode:
00:00 Introduction to Success in Biotech
00:16 Understanding the Main Risks in Biotech
00:44 Meet the Leader: Peter M. Kovacs
01:06 The PMK Group Difference
01:42 Minimizing Technical Failures
02:09 Supporting Biotech and MedTech Companies
02:32 Vision for the Future
02:58 Call to Collaborate
Links:
Peter M. Kovacs LinkedIn: https://www.linkedin.com/in/petermkovacs/
Peter M. Kovacs Personal Website:https://www.petermkovacs.com/
PMK Group Website: https://www.pmk-group.com/
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com
The Herd with Colin Cowherd
The Herd with Colin Cowherd is a thought-provoking, opinionated, and topic-driven journey through the top sports stories of the day.